Insulin glargine for type 2 diabetes
Canadian Coordinating Office for Health Technology Assessment
Record ID 32004000801
English, French
Authors' objectives:
To summarize the available information on the use of insulin glargine (Trade Mark: Lantus) - a biosynthetic, long-acting human insulin analogue - to treat type 2 diabetes.
Authors' recommendations:
Patients who have adequate glycemic control and minimal hypoglycemic events with NPH insulin will likely not derive additional benefit from insulin glargine (in most studies, insulin glargine did not significantly reduce fasting blood glucose, fasting plasma glucose, or hemoglobin A1c compared to NPH insulin). They may, however, find once-daily dosing more convenient. Most trials showed a statistically significant decrease in the incidence of nocturnal and symptomatic hypoglycemia. This may not be as much of a concern in most patients with type 2 compared to type 1. The long-term safety and lower cost of NPH insulin compared with insulin glargine could limit its implementation.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/
Year Published:
2004
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Costs and Cost Analysis
- Diabetes Mellitus, Type 2
- Insulin
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.